

Supplementary Online Content


Scragg R, Khaw K-T, Toop L, et al. Monthly high-dose vitamin D supplementation and cancer risk: a post hoc analysis of the Vitamin D Assessment randomized clinical trial. *JAMA Oncol*. Published online July 19, 2018. doi:10.1001/jamaoncol.2018.2178

eFigure. Mean (95% CI) Observed 25-Hydroxyvitamin D Concentration During Follow-up in the Random Subsample, by Treatment Group

eTable. Subgroup Analysis for Secondary Outcomes

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. Mean (95% CI) Observed 25-Hydroxyvitamin D Concentration During Follow-up in the Random Subsample, by Treatment Group.



eTable. Subgroup Analysis for Secondary Outcomes. Proportion of Participants Having Incident Cancer or Dying of Cancer, During Follow-up, and Hazard Ratios Adjusted for Age, Sex, and Race/Ethnicity, by Study Treatment Group.

Secondary outcome	Vitamin D N of events (%)	Placebo N of events (%)	Adjusted Hazard Ratio (95% CI)	P-value (Wald χ^2)
Cancer registrations: randomization to 31 December 2015				
Males	124 (8.2)	122 (8.4)	0.99 (0.77, 1.27)	0.94
Females	64 (6.1)	65 (5.9)	1.01 (0.71, 1.42)	0.98
25(OH)D <20 ng/mL	43 (7.0)	51 (7.8)	0.96 (0.64, 1.44)	0.84
25(OH)D ≥20 ng/mL	145 (7.5)	136 (7.2)	1.04 (0.82, 1.31)	0.75
Cancer registrations: one year after randomization to 31 July 2015				
Males	72 (4.8)	84 (5.8)	0.84 (0.61, 1.15)	0.27
Females	44 (4.2)	38 (3.5)	1.17 (0.76, 1.81)	0.48
25(OH)D <20 ng/mL	25 (4.1)	33 (5.0)	0.89 (0.52, 1.50)	0.65
25(OH)D ≥20 ng/mL	91 (4.7)	89 (4.7)	1.01 (0.75, 1.35)	0.97
Cancer registrations: one year after randomization to 31 Dec 2015				
Males	88 (5.8)	96 (6.6)	0.89 (0.67, 1.19)	0.44
Females	51 (4.9)	50 (4.6)	1.04 (0.70, 1.54)	0.84
25(OH)D <20 ng/mL	31 (5.1)	42 (6.4)	0.85 (0.53, 1.36)	0.49
25(OH)D ≥20 ng/mL	108 (5.5)	104 (5.5)	1.02 (0.78, 1.33)	0.91
All cancer deaths: randomization to 31 December 2015 ^a				
Males	32 (2.1)	34 (2.3)	0.93 (0.58, 1.50)	0.76
Females	12 (1.1)	11 (1.0)	1.07 (0.46, 2.47)	0.87
25(OH)D <20 ng/mL	16 (2.6)	12 (1.8)	1.57 (0.74, 3.33)	0.24
25(OH)D ≥20 ng/mL	28 (1.4)	33 (1.7)	0.82 (0.50, 1.36)	0.45

^a includes deaths from cancer diagnosed before randomization.